Fertility drug trial aims to stop dangerous treatment side effect
NCT ID NCT07043322
Summary
This study is testing if a medication called cabergoline can better prevent a serious complication called Ovarian Hyperstimulation Syndrome (OHSS) in women undergoing fertility treatments. It will compare cabergoline to the current standard method of delaying a hormone injection. The goal is to find a safer way to protect women at high risk for this condition during their fertility journey.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mostafa Bahaa
RECRUITINGDamietta, New Damietta, 34518, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.